Kymera Therapeutics Inc (NAS:KYMR)

$ 47.74 0.89 (1.9%) Market Cap: 3.09 Bil Enterprise Value: 2.57 Bil PE Ratio: 0 PB Ratio: 3.46 GF Score: 50/100

Q3 2024 Kymera Therapeutics Inc Earnings Call Transcript
Oct 31, 2024

$46.17 (-3.15%)

Earnings
Q2 2024 Kymera Therapeutics Inc Earnings Call Transcript
Aug 07, 2024

$40.31 (-2.68%)

Earnings
Q1 2024 Kymera Therapeutics Inc Earnings Call Transcript
May 02, 2024

$36.3 (+0.17%)

Earnings
Q4 2023 Kymera Therapeutics Inc Earnings Call Transcript
Feb 22, 2024

$40.49 (+4.71%)

Earnings
Kymera Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 09, 2024
Kymera Therapeutics Inc Virtual Immunology R&D Day Transcript
Jan 04, 2024
Kymera Therapeutics Inc at UBS BioPharma Conference Transcript
Nov 08, 2023
Q3 2023 Kymera Therapeutics Inc Earnings Call Transcript
Nov 02, 2023

$12.08 (+4.59%)

Earnings
Kymera Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2023
Q2 2023 Kymera Therapeutics Inc Earnings Call Transcript
Aug 03, 2023

$23.88 (+11.07%)

Earnings
Kymera Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript
Jun 14, 2023
Kymera Therapeutics Inc at Bank of America Global Healthcare Conference Transcript
May 10, 2023
Q1 2023 Kymera Therapeutics Inc Earnings Call Transcript
May 04, 2023

$26.24 (-15.08%)

Earnings
Q4 2022 Kymera Therapeutics Inc Earnings Call Transcript
Feb 23, 2023

$33.16 (+5.17%)

Earnings
Kymera Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 10, 2023
Kymera Therapeutics Inc Investor Webcast KT-474 Clinical Update Call Transcript
Dec 14, 2022
Kymera Therapeutics Inc at Bank of America Biotech SMID Cap Conference Transcript
Dec 07, 2022
Kymera Therapeutics Inc at Credit Suisse Healthcare Conference Transcript
Nov 09, 2022
Q3 2022 Kymera Therapeutics Inc Earnings Call Transcript
Nov 03, 2022

$30.92 (+7.55%)

Earnings
Kymera Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 14, 2022
Q2 2022 Kymera Therapeutics Inc Earnings Call Transcript
Aug 09, 2022

$30.35 (-3.44%)

Earnings
Kymera Therapeutics Inc at UBS Global Healthcare Conference Transcript
May 23, 2022
Kymera Therapeutics Inc at Bank of America Healthcare Conference Transcript
May 12, 2022
Q1 2022 Kymera Therapeutics Inc Earnings Call Transcript
May 03, 2022

$24.88 (-23.98%)

Earnings
Kymera Therapeutics Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript
Feb 10, 2022
Kymera Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 11, 2022
Kymera Therapeutics Inc To Host Virtual R&D Day Transcript
Dec 16, 2021
Kymera Therapeutics Inc at Evercore ISI HealthCONx Virtual Conference Transcript
Dec 01, 2021
Kymera Therapeutics Inc at Credit Suisse Healthcare Conference (Virtual) Transcript
Nov 11, 2021
Kymera Therapeutics Inc To Discuss Data From KT-474 Phase 1 Trial Call Transcript
Oct 27, 2021
Kymera Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 09, 2021
Kymera Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 09, 2021
Kymera Therapeutics Inc at UBS Global Healthcare Virtual Conference Transcript
May 25, 2021
Kymera Therapeutics Inc Presenting at Bank of America Global Research Healthcare Conference (Virtual) Transcript
May 13, 2021
Kymera Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 14, 2021

Q2 2024 Kymera Therapeutics Inc Earnings Call Transcript

Aug 07, 2024 / 12:30PM GMT

Release Date Price: $40.31 (-2.68%)

Transcript 10-Q8-K

Operator

Good day and welcome to the Kymera Therapeutics second quarter 2024 results call. (Operator instructions) Please note this event is being recorded. I would now like to turn the conference over to Justine Koenigsberg, Head of Investor Relations. Please go ahead.

Justine Koenigsberg

Kymera Therapeutics Inc - Vice President - Investor Relations

Good morning and welcome to Kymera's quarterly update call. Joining me this morning are Nello Mainolfi, President and CEO; Jared Gollob, our Chief Medical Officer; and Bruce Jacobs, our Chief Financial Officer. Following our prepared remarks, we will open the call to questions. In order to have enough time to address everyone's questions, please limit your questions to one and a relevant follow-up.

Before we begin, I would like to remind you that today's discussion will include forward-looking statements about our future expectations, plans and prospects. These statements are subject to risks and uncertainties that may cause actual results to differ materially from those projected.

A description of these

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.